⁶⁸Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer

Abstract

This study was designed to assess the diagnostic value of 68Ga-NOTA-PRGD2 (NOTA-PRGD2 is NOTA-PEG4-E[c(RGDfK)]2) PET/CT in lung cancer. Methods Ninety-one patients (48 men and 43 women; age, 22–82 y) with suspected lung lesions on CT were enrolled with informed consent. Immediately after intravenous injection of 117.7 ± 37.7 MBq of 68Ga-NOTA-PRGD2, 15 patients underwent dynamic whole-body PET/CT scans for 1–2 h, and the remaining 76 patients underwent whole-body PET/CT scans at 30 ± 10 min after bolus injection. Each patient also underwent standard 18F-FDG PET/CT for comparison. Results No side effect was found after 68Ga-NOTA-PRGD2 injection. 68Ga-NOTA-PRGD2 was rapidly cleared from the blood pool and primarily excreted through the urinary system. The standardized uptake values of proven malignancies were significantly higher than those of the benign ones. With an average standardized uptake value of greater than 1.3 being considered malignant, the sensitivity, specificity, and accuracy of 68Ga-NOTA-PRGD2 PET/CT in diagnosing lung cancer were 83.8% (57/68), 91.3% (21/23), and 85.7% (78/91), respectively. The diagnostic value of 68Ga-NOTA-PRGD2 for lung cancer is comparable to that of 18F-FDG PET/CT. However, 68Ga-NOTA-PRGD2 PET/CT is more specific than 18F-FDG PET/CT in assessing lymph node metastasis, with positive and negative predictive values of 90.0% (27/30) and 93.8% (121/129), respectively, whereas those of 18F-FDG PET/CT were 30.2% (29/96) and 90.5% (57/63), respectively. Conclusion This study indicates the efficacy of 68Ga-NOTA-PRGD2 PET/CT in lung cancer diagnosis. 68Ga-NOTA-PRGD2 PET/CT shows significant advantage over 18F-FDG PET/CT in judging metastatic lymph nodes with higher specificity.

The uptake exploration of 68Ga-labeled NGR in well-differentiated hepatocellular carcinoma xenografts: Indication for the new clinical translational of a tracer based on NGR

“…The development of radio-labeled peptide probes, such as RGD and NGR, for diagnostic and therapeutic applications, has rapidly expanded in the last decades (34)(35)(36)(37). On the aspect of clinical practice, the safety and the applicability of these probes have been well established in lung cancer (38)(39)(40), brain metastases (41), breast cancer (42) and rheumatoid arthritis (43). Even though HCCs are worldwide malignant tumors with high incidence of morbidity, there has been little progress in their detection by radio-labeled probes.…”

Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology

“…Intermediate uptake is found in the liver, spleen, and intestines. Reproduced with the permission from [5,45,47,190,[207][208][209][210].…”

The role of new PET tracers for lung cancer

“…68 Ga NOTA-RGD is the first 68 Ga-labeled integrin-targeting compound for which initial clinical data is available. A study by Zheng et al suggested that the diagnostic value of 68 Ga-NOTA-PRGD2 for lung cancer diagnosis was comparable to 18 F-FDG with a significant advantage over 18 F-FDG in identifying metastatic lymph nodes with greater specificity (67).…”